Thus, our results suggest that even when using therapeutic doses of anticoagulants in elderly patients with COVID-19, the increased risk of thrombotic complications in viral infections in carriers of G1691A mutations in the FV gene, and G20210A and C494T in the FII gene should be considered, which requires increased coagulogram monitoring and intensified methods of treatment correction. This evidence concerns the gene F5 and COVID-19.